department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

RIFADIN · pharmadog

pharmadog
drugs
RIFADIN

patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

← back to professional view

drug

RIFADIN

Marketedupdated 2mo ago

by Sanofi-Aventis US LLC

Approved

community read0 votes

all catalysts(100)

approval · 100

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

view all 100 catalysts →

News(0)

no news has mentioned this drug yet

brand

RIFADIN

generic

RIFAMPIN

indication

Tuberculosis

phase

marketed

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

RIFADIN (RIFAMPIN) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 11m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 8

tagApproval464 co-mentions · 116 sources
drugrifampin235 co-mentions · 119 sources
company$SNYSanofi233 co-mentions · 117 sources
company$SNYNFSanofi233 co-mentions · 117 sources
tagSmall Molecule176 co-mentions · 88 sources
tagDrug Shortage3 co-mentions · 3 sources
companyMylan Institutional Inc1 co-mentions · 1 sources
companyEpic Pharma LLC1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying RIFADIN

phase2Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBcompletedn=122
phase1Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participantsnot yet recruitingn=28
phase1This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazolecompletedn=32
phase1An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participantsrecruitingn=60
phase1A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participantsrecruitingn=42
phase1Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccinescompletedn=20
phase1Drug to Drug Interaction Study of KBP-5074 in Healthy Subjectscompletedn=24
phase1A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participantscompletedn=63

more trials →